Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
Recruiting now · Phase 1
Conditions studied: Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy
In brief
A total of 17 to 23 participants are anticipated to be enrolled in the Phase I clinical trial, which is further divided into two distinct parts: one part involves single-agent cell therapy, while the other entails a combination of cell therapy and Serplulimab Injection. To be more precise, the study aims to include patients who have been diagnosed with metastatic or locally advanced refractory/recurrent malignant solid tumors and have shown resistance to standard therapeutic interventions. These tumor types may encompass head and neck cancer, ovarian cancer, lung cancer, melanoma, and others.
Key facts
- Study ID
- NCT06302062
- Run by
- Guangzhou FineImmune Biotechnology Co., LTD.
- People needed
- 23
- Starts
- 2023-06-06
- Expected to finish
- 2026-06-30
- Last updated by the study team
- 2024-12-03
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Sun Yat-sen University Cancer Center — Guangzhou, Gaungdong, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.